
Alto Neuroscience Shares Phase 2b Results for ALTO-100 in Major Depression
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on innovative treatments for neuropsychiatric disorders, announced today that its Phase 2b trial of ALTO-100 for major depressive disorder (MDD)…












